Jeffery Vainshtein, MD
Radiation Oncology · White Plains, NYNPI 1518109842
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Novocure Inc. accounts for 75.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $2,500 and has fallen 88.0% since, to $300 in 2025.
Across 7 payments — averaging $867.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$5K
- AstraZeneca$1K
- BD$300
- Medtronic$158
What the payments were for
- Consulting fees$3,22553%
- Speaking & faculty fees$2,50041%
- Travel & lodging$1883%
- Food & beverage$1583%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 3 | $4,563 |
| AstraZeneca | 2 | $1,050 |
| BD | 1 | $300 |
| Medtronic | 1 | $158 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oncology$2,500
- TAGRISSO$525
- IMFINZI$525
- PTEYE PARATHYROID DETECTION SYSTEM$158
How this compares
$6,072 in reported general payments places this provider in the 85th percentile of 397 radiation oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl ErMemantine Hcl | 15 | $1,723 |
| Tamsulosin Hcl | 69 | $567 |
| Gabapentin | 44 | $498 |
| Lidocaine Hcl ViscousLidocaine Hcl | 28 | $400 |
| Oxycodone Hcl | 12 | $388 |
| Glycopyrrolate | 13 | $238 |
| Dexamethasone | 15 | $135 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in White Plains
- Randy StevensWhite Plains$8K
- Chung ChungSyracuse$3.1M
- Michael ZelefskyNew York$946K
- Jeffrey BogartSyracuse$772K
- Steven FinkelsteinSyracuse$578K
- Shawn ZimbergPlainview$411K
- Edward ObedianOyster Bay$391K
- Nancy LeeNew York$233K
- Dheerendra PrasadBuffalo$178K
- Robert SamsteinNew York$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.